Every Form 4 that Jupiter Neurosciences, Inc. (JUNS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow JUNS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JUNS filings page.
JUPITER NEUROSCIENCES, INC. reported that director Andrew Jon Cutler received a grant of 472,222 stock options under the 2025 Equity Incentive Plan in connection with his appointment to the Board of Directors, in lieu of cash annual board retainer and committee fees.
The options give the right to purchase 472,222 shares of Common Stock at an exercise price of $0.0900 per share, expire on July 31, 2036, and vest with 25 % upfront and the remainder in three quarterly installments beginning February 1, 2026, subject to continued service as a director.
JUPITER NEUROSCIENCES, INC. director Julie B. Kampf reported the vesting and exercise of 82,875 restricted stock units on June 2, 2025. These RSUs converted into common stock on a one-for-one basis at $0.00 per unit upon expiration of the IPO lock-up period, leaving her with 82,875 common shares held directly.
JUPITER NEUROSCIENCES, INC. Chief Administrative Officer Alexander Gustaf Erik Rosen exercised equity awards into common stock. On 2 June 2025, he converted 96,608 Restricted Stock Awards and 164,554 Restricted Stock Units, each on a one-for-one basis into common shares at a $0.0000 exercise price, following the expiration of the IPO lock-up period.
Jupiter Neurosciences, Inc. director and Chief Scientific Officer Hayward Marshall A. reported multiple equity award exercises that increased his direct common stock holdings. On June 2, 2025 he exercised restricted stock awards and restricted stock units for a combined 789,195 shares of common stock. On March 2, 2026 he exercised a stock option for 225,000 shares of common stock at a conversion price of $0.01 per share, ahead of the option’s March 15, 2026 expiration. In total, the transactions reflect exercises of 1,014,195 shares from derivative awards into common stock, resulting in 2,995,077 common shares held directly after the most recent transaction. Footnotes state that the derivative securities convert into common stock on a one-for-one basis and that certain awards vested upon expiration of the IPO lock-up period or under the company’s 2016 Equity Incentive Plan.
Jupiter Neurosciences, Inc. director Nicholas H. Hemmerly exercised restricted stock units into common stock. On June 2, 2025, 95,550 restricted stock units converted on a one-for-one basis into 95,550 shares of common stock, vesting upon expiration of the lock-up period for the company’s initial public offering. Following the transaction, Hemmerly holds 95,550 common shares directly, and the reported restricted stock unit position is reduced to zero. The event reflects equity compensation vesting rather than an open-market purchase or sale.
JUPITER NEUROSCIENCES, INC. director Holger Weis exercised 85,800 Restricted Stock Units that converted into an equal number of common shares on June 2, 2025. The RSUs vested upon expiration of the lock-up period for the company’s initial public offering. Following the transaction, Weis holds 96,581 common shares directly.
JUPITER NEUROSCIENCES, INC. director Tomas Jan Philipson received a grant of stock options as board compensation. He was awarded 536,428 stock options, each for one share of common stock at an exercise price of $0.21 per share. Of this grant, 90,000 options relate to his appointment to the Board of Directors, and 446,428 options were granted instead of cash for his annual board retainer and committee fees. The options vest in 12 equal quarterly installments beginning on September 2, 2026, as long as he continues to serve as a director through each vesting date, and are scheduled to expire on June 29, 2036.
JUPITER NEUROSCIENCES, INC. director Brady Allison W received a grant of stock options covering 100,000 shares of common stock. The options have an exercise price of $0.2783 per share and expire on June 2, 2036.
The grant was made under the company’s 2025 Equity Incentive Plan. The options vest over three years starting September 2, 2026, in equal quarterly installments, and require continued service through each vesting date. Following this award, the filing shows 100,000 derivative securities held directly.
JUPITER NEUROSCIENCES, INC. reported a compensation-related stock option grant to its Chief Financial Officer, Saleem Elmasri. He received options for 525,565 shares of common stock at an exercise price of $0.2783 per share, expiring on June 2, 2036.
According to the disclosure, 325,565 options were granted as a discretionary bonus for services during fiscal 2025 and 200,000 options were granted as long-term incentive compensation under the 2025 Equity Incentive Plan. The options vest over three years starting from September 2, 2026 in equal quarterly installments, conditioned on continued employment through each vesting date.
Jupiter Neurosciences CEO and Chairman Christer Rosen received a grant of 747,783 stock options for common stock. The options have an exercise price of $0.2783 per share and expire on June 2, 2036, giving him the right to buy shares at that price in the future.
According to the disclosure, the options were granted under the company’s 2025 Equity Incentive Plan as a discretionary bonus for services during fiscal 2025. They vest over three years starting on September 2, 2026, in equal quarterly installments, contingent on Rosen’s continued employment.
Jupiter Neurosciences director Nicholas H. Hemmerly received a grant of stock options covering 100,000 shares of Common Stock. The options have an exercise price of $0.2783 per share and expire on June 2, 2036. They were granted under the company’s 2025 Equity Incentive Plan and vest over three years beginning on September 2, 2026, in equal quarterly installments, subject to his continued service through each vesting date. Following this grant, Hemmerly holds options for 100,000 underlying shares directly.
JUPITER NEUROSCIENCES, INC. director Julie B. Kampf received a grant of stock options covering 100,000 shares of common stock. The options have an exercise price of $0.2783 per share and expire on June 2, 2036.
These options were granted under the company’s 2025 Equity Incentive Plan. They vest over three years in equal quarterly installments, beginning on September 2, 2026, as long as she continues to provide service through each vesting date. Following this grant, her reported option holdings from this award total 100,000 shares.
JUPITER NEUROSCIENCES, INC. reported that President and COO Alison D. Silva received a grant of stock options covering 1,027,304 shares of common stock at an exercise price of $0.2783 per share.
According to the footnote, 427,304 of these options were granted as a discretionary bonus for services during fiscal 2025, and 600,000 options were granted as long-term incentive compensation under the company’s 2025 Equity Incentive Plan. The options vest over three years, in equal quarterly installments starting on September 2, 2026, subject to continued employment, and this grant brings Silva’s reported derivative holdings to 1,027,304 options.
Jupiter Neurosciences, Inc. reported that Chief Scientific Officer Hayward Marshall received a grant of 259,231 stock options on June 2, 2026 as a discretionary bonus for services during fiscal 2025. The options have an exercise price of $0.2783 per share and expire on June 2, 2036.
The options relate to 259,231 shares of common stock and were granted under the company’s 2025 Equity Incentive Plan. They vest over three years starting September 2, 2026, in equal quarterly installments, contingent on Mr. Marshall’s continued employment, and his total options following this grant are 259,231.
Jupiter Neurosciences director Holger Weis received a grant of stock options covering 100,000 shares of common stock. The options have an exercise price of $0.2783 per share and expire on June 2, 2036. They were granted under the company’s 2025 Equity Incentive Plan and vest over three years starting on September 2, 2026, in equal quarterly installments, subject to continued service.
JUPITER NEUROSCIENCES, INC. granted Chief Administrative Officer Alexander Gustaf Erik Rosen a stock option award covering 341,843 shares of common stock. The options have an exercise price of $0.2783 per share and expire on June 2, 2036.
The grant was made as a discretionary bonus for services rendered during fiscal 2025 under the company’s 2025 Equity Incentive Plan. The options vest over three years starting September 2, 2026, in equal quarterly installments, subject to Rosen’s continued employment through each vesting date.